Literature DB >> 20859389

How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors.

Ting Bao, Nancy E Davidson.   

Abstract

Entities:  

Year:  2007        PMID: 20859389      PMCID: PMC2793755          DOI: 10.1200/JOP.0768501

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  11 in total

1.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Authors:  Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

2.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Authors:  Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

3.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.

Authors:  F Boccardo; A Rubagotti; P Guglielmini; A Fini; G Paladini; M Mesiti; M Rinaldini; S Scali; M Porpiglia; C Benedetto; N Restuccia; F Buzzi; R Franchi; B Massidda; V Distante; D Amadori; P Sismondi
Journal:  Ann Oncol       Date:  2006-06       Impact factor: 32.976

5.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

6.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Authors:  R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

Authors:  Bruce E Hillner; James N Ingle; Rowan T Chlebowski; Julie Gralow; Gary C Yee; Nora A Janjan; Jane A Cauley; Brent A Blumenstein; Kathy S Albain; Allan Lipton; Susan Brown
Journal:  J Clin Oncol       Date:  2003-09-08       Impact factor: 44.544

Review 9.  Sex steroids and the construction and conservation of the adult skeleton.

Authors:  B Lawrence Riggs; Sundeep Khosla; L Joseph Melton
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

Review 10.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.